Published in Antimicrob Agents Chemother on November 01, 1992
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A (1993) 6.14
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A (1999) 3.03
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 2.38
New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. J Nat Prod (2003) 1.81
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother (1994) 1.43
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest (1995) 1.42
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother (1995) 1.38
Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. J Nat Prod (2004) 1.36
Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother (1994) 1.33
Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog (2014) 1.32
Manadomanzamines A and B: a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. J Am Chem Soc (2003) 1.27
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. J Nat Prod (2006) 1.25
Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Antimicrob Agents Chemother (1993) 1.23
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother (1994) 1.23
Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. Antimicrob Agents Chemother (1992) 1.20
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother (2001) 1.17
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother (1997) 1.14
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother (1994) 1.12
Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother (1994) 1.07
Tautomerism in drug discovery. J Comput Aided Mol Des (2010) 1.05
New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis (2009) 1.03
HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. Mol Biol Int (2012) 1.00
Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J Biol Chem (2008) 0.99
The 5'-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 0.99
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol (1997) 0.95
Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. J Virol (2001) 0.95
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (2004) 0.93
Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues. Biochem J (1997) 0.93
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 0.92
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob Agents Chemother (1993) 0.92
A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrob Agents Chemother (1999) 0.89
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob Agents Chemother (1994) 0.87
Chemical transformation and biological studies of marine sesquiterpene (S)-(+)-curcuphenol and its analogs. Biochim Biophys Acta (2007) 0.86
Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother (1993) 0.82
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology (2013) 0.79
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79
Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob Agents Chemother (2000) 0.79
Strong and selective inhibitors of hepatitis B virus replication among novel N4-hydroxy- and 5-methyl-beta-L-deoxycytidine analogues. Antimicrob Agents Chemother (2007) 0.78
Therapy of HIV Infection: Current Approaches and Prospects. Acta Naturae (2017) 0.78
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ. Proc Natl Acad Sci U S A (2015) 0.77
Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells. World J Gastroenterol (2008) 0.77
Intracellular metabolism of beta-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activity. Antimicrob Agents Chemother (2000) 0.77
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2005) 0.77
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. Eur J Med Chem (2011) 0.76
Structural and kinetic insights into binding and incorporation of L-nucleotide analogs by a Y-family DNA polymerase. Nucleic Acids Res (2014) 0.76
Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5. Antimicrob Agents Chemother (2014) 0.76
Synthesis and anti-HIV activity of D- and L-thietanose nucleosides. J Med Chem (2006) 0.75
Toward the development of a single-round infection assay based on EGFP reporting for anti-HIV-1 drug discovery. Rep Biochem Mol Biol (2015) 0.75
Structural basis for the binding and incorporation of nucleotide analogs with L-stereochemistry by human DNA polymerase λ. Proc Natl Acad Sci U S A (2014) 0.75
Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine. Antimicrob Agents Chemother (2005) 0.75
Review of tenofovir-emtricitabine. Ther Clin Risk Manag (2007) 0.75
Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One (2014) 0.75
Structural basis for the D-stereoselectivity of human DNA polymerase β. Nucleic Acids Res (2017) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol (1980) 287.68
The determination of enzyme inhibitor constants. Biochem J (1953) 27.58
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A (1991) 5.83
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother (1992) 2.58
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1990) 2.53
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother (1992) 2.17
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. AIDS Res Hum Retroviruses (1992) 1.47
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother (1991) 1.45
Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun (1989) 1.44
Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother (1987) 1.41
Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1988) 1.40
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother (1988) 1.36
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol (1989) 1.32
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemother (1990) 1.22
Anti-HIV compound assessment by two novel high capacity assays. J Virol Methods (1989) 1.20
In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV). Antiviral Res (1990) 1.07
Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate. Antimicrob Agents Chemother (1989) 1.00
Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy. Intervirology (1989) 0.90
Antiretroviral activity, biochemistry, and pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine. Ann N Y Acad Sci (1990) 0.90
Metabolism of pyrimidine L-nucleosides. Nucleic Acids Res (1976) 0.89
Pharmacologic studies of nucleosides active against the human immunodeficiency virus. Ann N Y Acad Sci (1990) 0.86
A gene map of the human genome. Science (1996) 14.32
A physical map of 30,000 human genes. Science (1998) 12.43
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A (1977) 11.20
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry (1983) 8.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic. JAMA (1988) 6.14
Neurological complications of pertussis inoculation. Arch Dis Child (1974) 6.12
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem (1978) 5.43
Pathological verification of ischemic score in differentiation of dementias. Ann Neurol (1980) 5.25
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther (1999) 4.65
Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J Virol (1979) 4.53
The ratio of 2nd to 4th digit length: a predictor of sperm numbers and concentrations of testosterone, luteinizing hormone and oestrogen. Hum Reprod (1998) 4.42
HIV in prisons. BMJ (1988) 3.81
Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet (1983) 3.79
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
A randomised controlled trial comparing two schedules of antenatal visits: the antenatal care project. BMJ (1996) 3.50
The use of a synthetic medium in the isolation of the somatic antigens of Bact. typhi-murium and Bact. typhosum. Biochem J (1940) 3.45
Benign intracranial hypertension following corticosteroid withdrawal in childhood. Br Med J (1970) 3.38
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet (1993) 3.36
Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol (1997) 3.24
Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol (1981) 3.18
Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br (2005) 2.94
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis (1997) 2.78
Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ (1996) 2.74
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res (1987) 2.71
Clearing the cataract backlog. Br J Ophthalmol (1987) 2.66
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
Risk factors for surgical site infection following caesarean section in England: results from a multicentre cohort study. BJOG (2012) 2.57
Characterization of lymphocyte responsiveness in early experimental syphilis. II. Nature of cellular infiltration and Treponema pallidum distribution in testicular lesions. J Immunol (1980) 2.53
A study of the "crossover population": aged persons entitled to both Medicare and Medicaid. Health Care Financ Rev (1983) 2.53
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1990) 2.53
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Adverse impact of surgical site infections in English hospitals. J Hosp Infect (2005) 2.51
Leber's hereditary optic atrophy: a possible defect of cyanide metabolism. Clin Sci (1965) 2.44
IgA deficiency, epilepsy, and phenytoin treatment. Lancet (1975) 2.40
Device-related sources of bacteraemia in English hospitals--opportunities for the prevention of hospital-acquired bacteraemia. J Hosp Infect (2003) 2.33
Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem (1981) 2.29
The genetic identity of acute infantile spinal muscular atrophy. Brain (1973) 2.26
Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. Pacing Clin Electrophysiol (1999) 2.24
Genetic analysis of assembly of the Salmonella enterica serovar Typhimurium type III secretion-associated needle complex. J Bacteriol (2001) 2.24
Narcotic analgesics and delayed gastric emptying during labour. Lancet (1975) 2.24
THE EFFECT OF ARTIFICIAL FEVER AND SPECIFIC ANTISERUM ON THE ORGANISMS PRESENT IN CASES OF TYPE III PNEUMOCOCCUS MENINGITIS. J Clin Invest (1938) 2.24
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother (1981) 2.21
Surface-active biomaterials. Science (1984) 2.21
Antagonism of tone and prostaglandin-mediated responses in a tracheal preparation by indomethacin and SC-19220. Br J Pharmacol (1974) 2.19
Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol (1975) 2.18
Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology (1980) 2.18
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother (1992) 2.17
Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol (1990) 2.14
Pertussis vaccine and serious acute neurological illness in children. Br Med J (Clin Res Ed) (1981) 2.13
Mitochondrial inheritance in a mitochondrially mediated disease. N Engl J Med (1983) 2.08
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest (1996) 2.07
Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev (2006) 2.06
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage (2001) 2.06
Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int (2006) 2.05
Psychometrics for two short forms of the Center for Epidemiologic Studies-Depression Scale. Issues Ment Health Nurs (1999) 2.05
Evaluation of an enzyme-linked immunosorbent assay for the detection of antibody to Trichomonas vaginalis in sera and vaginal secretions. Br J Vener Dis (1982) 2.04
Dementia and depression among the elderly living in the Hobart community: the effect of the diagnostic criteria on the prevalence rates. Psychol Med (1985) 2.02
A cohort study of health care workers to assess nosocomial transmissibility of Nipah virus, Malaysia, 1999. J Infect Dis (2001) 2.02
Predictive model for wall-bounded turbulent flow. Science (2010) 1.99
The dually entitled elderly Medicare and Medicaid population living in the community. Health Care Financ Rev (1984) 1.99
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Susceptibility-induced loss of signal: comparing PET and fMRI on a semantic task. Neuroimage (2000) 1.97
Bacterial vaginosis: a public health review. BJOG (2001) 1.95
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol (1981) 1.92
Screening for treponemal infection by a new enzyme immunoassay. Genitourin Med (1989) 1.88
Measurement of the rate of nu(e) + d --> p + p + e(-) interactions produced by (8)B solar neutrinos at the Sudbury Neutrino Observatory. Phys Rev Lett (2001) 1.88
Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother (1987) 1.86
Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. J Epidemiol Community Health (1986) 1.85
Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine. Proc Natl Acad Sci U S A (1993) 1.84
Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. J Biol Chem (1984) 1.83
Metabolic inter-relationships between cyanide, thiocyanate and vitamin B 12 in smokers and non-smokers. Clin Sci (1966) 1.81
Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation (1982) 1.81
Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci (1996) 1.80
Mechanisms of the pressor and depressor actions of St 155 (2-(2,6--dichlorophenylamino)-2-imidazoline hydrochloride, Catapres). Eur J Pharmacol (1968) 1.80
Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med (1994) 1.80
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine. J Virol (1982) 1.79
Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J Immunol (1993) 1.78
Sexual assault of men: a series. Genitourin Med (1990) 1.77
Emotional reactions to radiation treatment. Cancer (1977) 1.77
Adherence of pilus- Opa+ gonococci to epithelial cells in vitro involves heparan sulfate. J Exp Med (1995) 1.77
A pharmacodynamic evaluation of midazolam as an antiepileptic compound. J Neurol Neurosurg Psychiatry (1986) 1.77
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
Value of computerised tomography in children with non-specific mental subnormally. Arch Dis Child (1982) 1.74
Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. J Virol (1981) 1.74